Allianz Asset Management Gmb H Crispr Therapeutics Ag Transaction History

Allianz Asset Management Gmb H

$65.6 Billion
Q2 2024

A detailed history of Allianz Asset Management Gmb H transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Allianz Asset Management Gmb H holds 3,800 shares of CRSP stock, worth $188,442. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,800

Previous 15,792 75.94%

Holding current value

$188,442

Previous $1.08 Million 80.95%

% of portfolio

0.0%

Previous 0.0%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$51.17 - $68.18 $613,630 - $817,614	-11,992 Reduced 75.94%	3,800 $205,000
Q1 2024 May 13, 2024	BUY	$60.67 - $89.12 $27,362 - $40,193	451 Added 2.94%	15,792 $1.08 Million
Q4 2023 Feb 12, 2024	BUY	$38.62 - $72.18 $50,206 - $93,834	1,300 Added 9.26%	15,341 $960,000
Q3 2023 Nov 13, 2023	SELL	$45.39 - $59.0 $1.89 Million - $2.46 Million	-41,722 Reduced 74.82%	14,041 $637,000
Q2 2023 Aug 11, 2023	BUY	$43.47 - $67.77 $74,420 - $116,022	1,712 Added 3.17%	55,763 $3.13 Million
Q1 2023 May 11, 2023	BUY	$41.0 - $56.12 $143,459 - $196,363	3,499 Added 6.92%	54,051 $2.44 Million
Q4 2022 Feb 13, 2023	BUY	$39.19 - $65.67 $8,190 - $13,725	209 Added 0.42%	50,552 $2.05 Million
Q3 2022 Nov 08, 2022	BUY	$61.1 - $83.78 $1.41 Million - $1.93 Million	23,071 Added 84.6%	50,343 $3.29 Million
Q1 2022 May 13, 2022	SELL	$53.19 - $79.24 $843,859 - $1.26 Million	-15,865 Reduced 36.78%	27,272 $1.71 Million
Q4 2021 Feb 11, 2022	BUY	$70.09 - $111.29 $75,346 - $119,636	1,075 Added 2.56%	43,137 $3.28 Million
Q3 2021 Nov 10, 2021	SELL	$110.2 - $156.64 $2.67 Million - $3.79 Million	-24,186 Reduced 36.51%	42,062 $4.71 Million
Q2 2021 Aug 16, 2021	BUY	$100.84 - $161.89 $4.08 Million - $6.54 Million	40,421 Added 156.51%	66,248 $10.7 Million
Q1 2021 May 13, 2021	BUY	$110.72 - $210.04 $416,639 - $790,380	3,763 Added 17.05%	25,827 $3.15 Million
Q4 2020 Feb 16, 2021	BUY	$79.67 - $173.23 $1.76 Million - $3.82 Million	22,064 New	22,064 $3.38 Million
Q2 2020 Aug 14, 2020	SELL	$38.5 - $76.05 $3.16 Million - $6.25 Million	-82,123 Closed	0 $0
Q1 2020 May 14, 2020	BUY	$33.68 - $62.53 $1.63 Million - $3.02 Million	48,316 Added 142.92%	82,123 $3.48 Million
Q4 2019 Feb 13, 2020	SELL	$36.68 - $73.13 $215,274 - $429,199	-5,869 Reduced 14.79%	33,807 $2.06 Million
Q3 2019 Nov 13, 2019	SELL	$40.99 - $52.56 $844,148 - $1.08 Million	-20,594 Reduced 34.17%	39,676 $1.64 Million
Q2 2019 Aug 08, 2019	SELL	$35.45 - $48.2 $682,270 - $927,657	-19,246 Reduced 24.2%	60,270 $2.84 Million
Q1 2019 May 13, 2019	BUY	$28.02 - $40.87 $480,935 - $701,492	17,164 Added 27.53%	79,516 $2.84 Million
Q4 2018 Feb 14, 2019	BUY	$22.73 - $42.34 $57,438 - $106,993	2,527 Added 4.22%	62,352 $1.75 Million
Q3 2018 Nov 13, 2018	SELL	$44.35 - $65.71 $2.91 Million - $4.31 Million	-65,632 Reduced 52.31%	59,825 $2.65 Million
Q2 2018 Aug 13, 2018	SELL	$42.62 - $73.59 $4.57 Million - $7.9 Million	-107,287 Reduced 46.1%	125,457 $7.37 Million
Q1 2018 May 14, 2018	BUY	$23.52 - $58.17 $16,087 - $39,788	684 Added 0.29%	232,744 $10.6 Million
Q4 2017 Feb 13, 2018	BUY	$16.95 - $23.48 $1.67 Million - $2.32 Million	98,690 Added 74.0%	232,060 $5.45 Million
Q3 2017 Nov 13, 2017	BUY	$16.75 - $20.66 $2.23 Million - $2.76 Million	133,370	133,370 $2.38 Million

Others Institutions Holding CRSP

# of Institutions

523

Shares Held

58M

Call Options Held

1.73M

Put Options Held

1.84M

View Full List

About CRISPR Therapeutics AG

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.87B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

More about CRSP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Allianz Asset Management Gmb H, based on Form 13F filings with the SEC.

News

Stay updated on Allianz Asset Management Gmb H with notifications on news.

Account

Allianz Asset Management Gmb H Crispr Therapeutics Ag Transaction History